Device-based nonspecific immunomodulation therapy (Celacade), and its potential role in the treatment of chronic heart failure

Cardiology in Review

Volumn 16, Issue 6, 2008, Pages 280-287

  Sporter, Robert J ^a   Kim, Joon Hyuk ^b   Frishman, William H ^c,d  

^a LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^b GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^c WESTCHESTER MEDICAL CENTER   (United States)

^d NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Autohemotherapy; Celacade; Chronic heart failure; Immunomodulation therapy

Indexed keywords

3 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)BICYCLO[2.2.2]OCTAN 1 YL]PROPIONIC ACID; ADALIMUMAB; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ETANERCEPT; INFLIXIMAB; NESIRITIDE; ROLOFYLLINE; TOLVAPTAN; VASODILATOR AGENT; ANTIINFLAMMATORY AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ACUTE HEART FAILURE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTERY DISEASE; BLOOD SAMPLING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EX VIVO STUDY; HEART FAILURE; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; INTERMITTENT CLAUDICATION; MORTALITY; NONHUMAN; OZONATION; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SKIN BLEEDING; TREATMENT OUTCOME; ULTRAVIOLET RADIATION; CHRONIC DISEASE; DRUG ANTAGONISM; DRUG EFFECT; IMMUNOLOGY; PATHOLOGY;

ANTI-INFLAMMATORY AGENTS; APOPTOSIS; CHRONIC DISEASE; HEART FAILURE; HUMANS; IMMUNOLOGIC FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 58149293460     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e318188591c     Document Type: Review

References (58)

1. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2005;112:1825-1852.
2. Tang WHW, Francis GS. The year in heart failure. J Am Coll Cardiol. 2007;50:2344-2351.
3. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000;83:596-602.
4. Sica DA, Gehr TW, Yancy C. Hyperkalemia, congestive heart failure, and aldosterone antagonism. Congest Heart Fail. 2003;9:224-229.
5. Noviasky JA. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide. Pharmacotherapy. 2007;27:626-632.
6. Gheorghiade M, Konstam MA, Burnett JC, et al. Short term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized with heart failure: the EVEREST clinical status trials. JAMA. 2007;297:1332-1343.
7. Konstam MA, Gheorghiade M, Burnett JC, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST outcome trial. JAMA. 2007;297:1319-1331.
8. Givertz MM, Massie BM, Fields TK, et al. The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. J Am Coll Cardiol. 2007;50:1551-1560.
9. Greenberg B, Thomas I, Banish D, et al. Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure. J Am Coll Cardiol. 2007;50:600-606.
10. Frishman WH, Zeidner J, NaseerN. Diagnosis and management of viral myocarditis. Curr Treat Options Cardiovasc Med. 2007;9:450-464.
11. Ramasubbu K, Oliveira G, Torre-Amione G. Novel therapies for heart failure: focus on anti-inflammatory strategies. Congest Heart Fail. 2006;12153-159.
12. Torre-Amione G. Immune activation in chronic heart failure. Am J Cardiol. 2005;95(Suppl):3C-8C.
13. Mann DL, Young JB. Basic mechanisms of heart failure: recognizing the role of proinflammatory cytokines. Chest. 1994;105:897-904.
14. nd ed. New York, NY: McGraw Hill; 2003: 705-739.
15. Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N EnglJ Med. 1990;223: 236-241.
16. Torre-Amione G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol. 1996;27:1201-1206.
17. Torre-Amione G, Kapadia S, Lee J, et al. Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation. 1996;93:704-711.
18. Mann D. Targeted anticytokine therapy and the failing heart. Am J Cardiol. 2005;95(Suppl):9C-16C.
19. Mann DL. Inflammatory mediators and the failing heart: past, present, and the foreseeable future. Circ Res. 2002;91:988-998.
20. Lauer B, Schannwell M, Kühl U, et al. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol. 2000;35:11-18.
21. Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation. 2000;101: 385-391.
22. Clark DJ, Cleman MW, Pfan SE, et al. Serum complement activation in congestive heart failure. Am Heart J. 2001;141:684-690.
23. Gong KZ, Song G, Spiers JP, et al. Activation of immune and inflammatory systems in chronic heart failure: novel therapeutic approaches. Int J Clin Pract. 2007;61:611-621.
24. Gullestad L, Aukrust P. Review of trials in chronic heart failure showing broad-spectrum anti-inflammatory approaches. Am J Cardiol. 2005; 95(Suppl):17C-23C.
25. Mielniczuk LM, Baughman KL. Immune modulation therapy in heart failure. Congest Heart Fail. 2006;1291-1296.
26. Mann DL, McMurray JJV, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized etanercept worldwide evaluation (RENEWAL). Circulation. 2004;109: 1594-1602.
27. Scallon BJ, Moore MA, Trinh H, et al. Chimeric anti-TNF-a monoclonal antibody cA2 binds recombinant transmembrane TNF-a and activates immune effector functions. Cytokine. 1995;7:251-259.
28. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-a, in patients with moderate-to-severe heart failure: results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation. 2003;107:3133-3140.
29. Bolton AE. Biologic effects and basic science of a novel immune-modulation therapy. Am J Cardiol. 2005;95(Suppl):24C-29C
30. Chandra J, Samali A, Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic Biol Med. 2000;29:323-333.
31. Voll RE, Herrmann M, Roth EA, et al. Immunosuppressive effects of apoptotic cells. Nature. 1997;390:350-351.
32. D'Orazio TJ, Niederkorn JY. A novel role for TGF-beta and IL-10 in the induction of immune privege. J Immunol. 1998;160:2089-2098.
33. Bellone M. Apoptosis, cross-presentation, and the fate of the antigen specific immune response. Apoptosis. 2000;5:307-314.
34. Bocci V. Ozonization of blood for the therapy of viral diseases and immunodeficiencies. A hypothesis. Med Hypothes. 1992;39:30-34.
35. Hernández F, Menéndez S, Wong R. Decrease of blood cholesterol and stimulation of antioxidative response in cardiopathy patients treated with endovenous ozone therapy. Free Radic Biol Med. 1995;19:115-119.
36. Tylicki L, Nieweglowski T, Biedunkiewicz B, et al. The influence of ozonated autohemotherapy on oxidative stress in hemodialyzed patients with atherosclerotic ischemia of lower limbs. Int J Artif Organs. 2003; 26:297-303.
37. Tylicki L, Nieweglowski T, Biedunkiewicz B, et al. Beneficial clinical effects of ozonated autohemo-therapy in chronically dialysed patients with atherosclerotic ischemia of the lower limbs - pilot study. Int J Artif Organs. 2001;24:79-82.
38. Immune modulation therapy - peripheral vascular disease - Vasogen (Vasocare). Drugs R D. 2002;3:358-360.
39. Visioli F. VasoCare. Vasogen. Curr Opin Investig Drugs. 2001;2:1247- 1249.
40. Shivji GM, Suzuki H, Mandel AS, et al. The effect of VAS972 on allergic contact hypersensitivity. J Cutan Med Surg. 2000;4:132-137.
41. Tremblay J, Chen H, Peng J, et al. Renal ischemia-reperfusion injury in the rat is prevented by a novel immune modulation therapy. Transplantation. 2002;74:1425-1433.
42. Nolan Y, Minogue A, Vereker E, et al. Attenuation of LPS-induced changes in synaptic activity in rat hippocampus by Vasogen's immune modulation therapy. Neuroimmunomodulation. 2002;10:40-46.
43. Babaei S, Stewart DJ, Picard P, et al. Effects of VasoCare therapy on the initiation and progression of atherosclerosis. Atherosclerosis. 2002;162: 45-53.
44. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol. 1999;135:1104-1110.
45. Vasogen Inc. Vasogen clinical trial identifies optimal treatment schedule in psoriasis. Media Release, March 14, 2002. Available at: http:// www.vasogen.com.
46. Weinberg JM, Saini R. Biologic therapy for psoriasis: the tumor necrosis factor inhibitors infliximab and etanercept. Cutis. 2003;71:25-29.
47. McGrath C, Robb R, Lucas AJ, et al. A randomised, double blind, placebo-controlled study to determine the efficacy of immune modulation therapy in the treatment of patients suffering from peripheral arterial occlusive disease with intermittent claudication. Eur J Vasc Endovasc Surg. 2002;23:381-387.
48. Vasogen Inc. SIMPADICO - study of immune modulation therapy in peripheral arterial disease and intermittent claudication outcomes. In: ClinicalTrials.gov. Bethesda, MD: National Library of Medicine. Available at: http://clinicaltrials.gov/show/NCT00111826. Accessed January 15, 2008.
49. Vasogen Inc. Vasogen announces the early close out of the SIMPADICO peripheral arterial disease trial. Media Release, August 30, 2005. Available at: http://www.vasogen.com.
50. Olin JW. A multicenter, randomized, double-blind, placebo-controlled study of immune modulation therapy in patients with symptomatic peripheral arterial disease: the SIMPADICO trial. Presented at: Smaller Late-Breaking Clinical Trials I, American College of Cardiology 55th Annual Scientific Sessions, March 11-14, 2006, Atlanta, GA.
51. Vasogen Inc. Vasogen announces results from Phase III SIMPADICO trial in peripheral arterial disease. Media Release, March 12, 2006. Available at: https://www.vasogen.com.
52. Torre-Amione G, Sestier F, Radovancevic B, et al. Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial. J Am Coll Cardiol. 2004;44:1181-1186.
53. Vasogen Inc. ACCLAIM - advanced chronic heart failure clinical assessment of immune modulation therapy. In: ClinicalTrials.gov. Be-thesda,MD: NationalLibraryofMedicine.Availableat:http://clinicaltrials. gov/show/NCT00111969. Accessed January 15, 2008.
54. Torre-Amione G, Bourge RC, Colucci W, et al. A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design. Can J Cardiol. 2007;23:369-376.
55. Torre-Amione G, Anker SD, Bourge RC, et al. Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial. Lancet. 2008;371:228-236.
56. Sliwa K, Ansari AA. Immunosuppression as therapy for congestive heart failure. Lancet. 2008;371:184-186.
57. Cleland JGF, Coletta AP, Clark AL. Clinical trials update from the joint European Society and the World Congress of Cardiology meeting: PEP-CHF, ACCLAIM and the HHH study. Eur J Heart Fail. 2006;8: 658-661.
58. Vasogen Inc. Vasogen and Grupo Ferrer announce initial roll-out of Celacade - new therapy for chronic heart failure. Media Release, December 17, 2007. Available at: http://www.vasogen.com.